Ciltacabtagene autoleucel

西达基奥仑赛

Report date: 2024/08/28 13:35:38

Base Information

Drug NameCiltacabtagene autoleucel
Drug Alias NameLCAR-B38M CAR-T cellsLCAR-B38M CAR-T细胞自体回输制剂LCAR-B38M cell productcilta-celCarvykti +[9] 
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Source of cells > PMBC-derived +[4] 
Mechanisms of ActionT lymphocyte replacementsB-cell maturation protein modulators
TargetsB-cell maturation protein
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsMultiple Myeloma
Approved Indications in ChinaMultiple Myeloma
Original Approved Country/TerritoryUnited States
Original Approved Date2022/02/28
Country/TerritoryCzechiaBelgiumCanada +[30] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNanjing Legend Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesJanssen-Cilag International NvLegend Biotech CorpJanssen Research & Development Llc +[4] 
Inactive CompaniesJanssen Pharmaceuticals Inc
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A